A Phase 3 interventional study of Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM) in Hemophilia A, sponsored by Baxalta now part of Shire. Terminated at 19 sites in 12 countries. Open to male participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2021-05-24.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 14th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 3, and was the 13th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
Runhui WU · Sites in China
Ages 0–18 · Men only
By country, each count listing its studies:
antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: Up to 1 Year · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2001; this study’s year is marked. 2 started in 2011.
This study's enrollment of 22 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 50 across the 21 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
47 studies in Hemophilia A by Takeda: none open now, 1 under way, none of them phase 3. Of 46 finished, 27 (59%) have results posted.
Among the 47 studies in Hemophilia A by Takeda, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2011, is one of 14 in phase 3, and was the 17th registered.
Takeda’s Hemophilia A studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 47 in Hemophilia A:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to assess if a once-weekly prophylactic regimen of 25 IU/kg ADVATE started at or before 1 year of age and before the onset of a severe bleeding phenotype (ie, joint bleeding), together with the minimization of immunological danger signals, can reduce the incidence rate of inhibitor formation in PUPs with severe and moderately severe hemophilia A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
Biological: Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Drug page: Antihemophilic factor, human recombinant
Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
Also known as: ADVATE
Number of Participants With Severe and Moderately Severe Hemophilia A (FVIII ≤ 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE
Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).
Time frame: 50 exposure days to ADVATE
Number of Participants With Severe Hemophilia A (FVIII ≤ 1%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE
Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).
Time frame: 50 exposure days to ADVATE
Number of Exposure Days of Treatment With Advate Prior to First Positive Factor VIII (FVIII) Confirmed Inhibitor Assessment
Confirmed inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 BU/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).
Time frame: 50 exposure days to ADVATE
Number of Participants With Low-titer, High-titer, Transient, and All Factor VIII (FVIII) Inhibitors
- High FVIII inhibitor titer (\> 5 Bethesda Unit (BU)/mL) - Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL)
Time frame: 50 exposure days to ADVATE
Number, Type, and Severity of All Bleeds Experienced When Different Prophylactic Dosing Frequencies Are Used (Once or Twice Per Week and Unknown Frequency)
Nominal Dosing Frequency: - 1 time per week - 2 times per week - Unknown dosing frequency (UK) Bleeding Type (BT): - Skin - Muscle and Soft Tissue - Mucosal - Joint - Other - Multiple - Total Bleeding severity: - Minor - Moderate - Severe - Total
Time frame: 50 exposure days to ADVATE
Number and Type of Surgeries
- Elective surgery is not allowed during period of first 20 exposure days (EDs) - Peripherally inserted central catheter (PICC)
Time frame: 50 exposure days to ADVATE
Correlation of Known Risk Factors to Factor VIII (FVIII) Inhibitor Formation
Time frame: 50 exposure days to ADVATE
Total Factor VIII (FVIII) Consumption by Participant
Time frame: 50 exposure days to ADVATE
FVIII-Specific Antibody Isotype for All Participants at Study Entry and Every 10 Exposure Days (EDs)
Time frame: 50 exposure days to ADVATE
Number of Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) at Least Possibly Related to ADVATE
Possibly or probably related adverse events
Time frame: 50 exposure days to ADVATE
Enrollment was conducted in Europe and North America at 19 clinical sites.
| Milestone | ADVATE - Prophylactic Regimen |
|---|---|
| Started | 19 |
| Completed | 3 |
| Not completed | 16 |
| Withdrew: Sponsor terminated study early | 8 |
| Withdrew: Low or high titer inhibitor | 8 |
Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).
| participants | ADVATE - Prophylactic Regimen |
|---|---|
| Number of Participants With Severe and Moderately Severe Hemophilia A (FVIII ≤ 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE | 8 |
Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).
| participants | ADVATE - Prophylactic Regimen |
|---|---|
| Number of Participants With Severe Hemophilia A (FVIII ≤ 1%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE | 8 |
Confirmed inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 BU/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).
| days | ADVATE - Prophylactic Regimen |
|---|---|
| Number of Exposure Days of Treatment With Advate Prior to First Positive Factor VIII (FVIII) Confirmed Inhibitor Assessment | 14.5 (7.0 to 21.0) |
- High FVIII inhibitor titer (\> 5 Bethesda Unit (BU)/mL) - Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL)
| participants | ADVATE - Prophylactic Regimen |
|---|---|
| Low FVIII inhibitor titer | 5 |
| High FVIII inhibitor titer | 3 |
| All FVIII inhibitors | 8 |
Nominal Dosing Frequency: - 1 time per week - 2 times per week - Unknown dosing frequency (UK) Bleeding Type (BT): - Skin - Muscle and Soft Tissue - Mucosal - Joint - Other - Multiple - Total Bleeding severity: - Minor - Moderate - Severe - Total
| Bleeds | ADVATE - Prophylactic Regimen |
|---|---|
| Dose: 1/week; Skin; Minor Bleed | 130 |
| Dose: 1/week; Skin; Moderate Bleed | 2 |
| Dose: 1/week; Skin; Severe Bleed | 0 |
| Dose: 1/week; Skin; Total Bleeds | 132 |
| Dose: 1/week; Muscle & Soft Tissue; Minor Bleed | 8 |
| Dose: 1/week; Muscle & Soft Tissue; Moderate Bleed | 10 |
| Dose: 1/week; Muscle & Soft Tissue; Severe Bleed | 0 |
| Dose: 1/week; Muscle & Soft Tissue; Total Bleeds | 18 |
| Dose: 1/week; Mucosal; Minor Bleed | 9 |
| Dose: 1/week; Mucosal; Moderate Bleed | 3 |
| Dose: 1/week; Mucosal; Severe Bleed | 0 |
| Dose: 1/week; Mucosal; Total Bleeds | 12 |
| Dose: 1/week; Joint; Minor Bleed | 0 |
| Dose: 1/week; Joint; Moderate Bleed | 0 |
| Dose: 1/week; Joint; Severe Bleed | 0 |
| Dose: 1/week; Joint; Total Bleeds | 0 |
| Dose: 1/week; Other BT; Minor Bleed | 3 |
| Dose: 1/week; Other BT; Moderate Bleed | 3 |
| Dose: 1/week; Other BT; Severe Bleed | 1 |
| Dose: 1/week; Other BT; Total Bleeds | 7 |
| Dose: 1/week; Multiple BT; Minor Bleed | 2 |
| Dose: 1/week; Multiple BT; Moderate Bleed | 1 |
| Dose: 1/week; Multiple BT; Severe Bleed | 0 |
| Dose: 1/week; Multiple BT; Total Bleeds | 3 |
| Dose: 1/week; Total BT; Minor Bleed | 152 |
| Dose: 1/week; Total BT; Moderate Bleed | 19 |
| Dose: 1/week; Total BT; Severe Bleed | 1 |
| Dose: 1/week; Total BT; Total Bleeds | 172 |
| Dose: 2/week; Skin; Minor Bleed | 9 |
| Dose: 2/week; Skin; Moderate Bleed | 0 |
| Dose: 2/week; Skin; Severe Bleed | 0 |
| Dose: 2/week; Skin; Total Bleeds | 9 |
| Dose: 2/week; Muscle & Soft Tissue; Minor Bleed | 0 |
| Dose: 2/week; Muscle & Soft Tissue; Moderate Bleed | 1 |
| Dose: 2/week; Muscle & Soft Tissue; Severe Bleed | 0 |
| Dose: 2/week; Muscle & Soft Tissue; Total Bleeds | 1 |
| Dose: 2/week; Mucosal; Minor Bleed | 3 |
| Dose: 2/week; Mucosal; Moderate Bleed | 1 |
| Dose: 2/week; Mucosal; Severe Bleed | 0 |
| Dose: 2/week; Mucosal; Total Bleeds | 4 |
| Dose: 2/week; Joint; Minor Bleed | 0 |
| Dose: 2/week; Joint; Moderate Bleed | 0 |
| Dose: 2/week; Joint; Severe Bleed | 0 |
| Dose: 2/week; Joint; Total Bleeds | 0 |
| Dose: 2/week; Other BT; Minor Bleed | 0 |
| Dose: 2/week; Other BT; Moderate Bleed | 0 |
| Dose: 2/week; Other BT; Severe Bleed | 0 |
| Dose: 2/week; Other BT; Total Bleeds | 0 |
| Dose: 2/week; Multiple BT; Minor Bleed | 0 |
| Dose: 2/week; Multiple BT; Moderate Bleed | 0 |
| Dose: 2/week; Multiple BT; Severe Bleed | 0 |
| Dose: 2/week; Multiple BT; Total Bleeds | 0 |
| Dose: 2/week; Total BT; Minor Bleed | 12 |
| Dose: 2/week; Total BT; Moderate Bleed | 2 |
| Dose: 2/week; Total BT; Severe Bleed | 0 |
| Dose: 2/week; Total BT; Total Bleeds | 14 |
| Dose: UK/week; Skin; Minor Bleed | 4 |
| Dose: UK/week; Skin; Moderate Bleed | 1 |
| Dose: UK/week; Skin; Severe Bleed | 0 |
| Dose: UK/week; Skin; Total Bleeds | 5 |
| Dose: UK/week; Muscle & Soft Tissue; Minor Bleed | 0 |
| Dose: UK/week; Muscle & Soft Tissue;Moderate Bleed | 1 |
| Dose: UK/week; Muscle & Soft Tissue; Severe Bleed | 0 |
| Dose: UK/week; Muscle & Soft Tissue; Total Bleeds | 1 |
| Dose: UK/week; Mucosal; Minor Bleed | 0 |
| Dose: UK/week; Mucosal; Moderate Bleed | 0 |
| Dose: UK/week; Mucosal; Severe Bleed | 0 |
| Dose: UK/week; Mucosal; Total Bleeds | 0 |
| Dose: UK/week; Joint; Minor Bleed | 0 |
| Dose: UK/week; Joint; Moderate Bleed | 1 |
| Dose: UK/week; Joint; Severe Bleed | 0 |
| Dose: UK/week; Joint; Total Bleeds | 1 |
| Dose: UK/week; Other BT; Minor Bleed | 0 |
| Dose: UK/week; Other BT; Moderate Bleed | 0 |
| Dose: UK/week; Other BT; Severe Bleed | 0 |
| Dose: UK/week; Other BT; Total Bleeds | 0 |
| Dose: UK/week; Multiple BT; Minor Bleed | 0 |
| Dose: UK/week; Multiple BT; Moderate Bleed | 0 |
| Dose: UK /week; Multiple BT; Severe Bleed | 0 |
| Dose: UK /week; Multiple BT; Total Bleeds | 0 |
| Dose: UK /week; Total BT; Minor Bleed | 4 |
| Dose: UK /week; Total BT; Moderate Bleed | 3 |
| Dose: UK /week; Total BT; Severe Bleed | 0 |
| Dose: UK /week; Total BT; Total Bleeds | 7 |
- Elective surgery is not allowed during period of first 20 exposure days (EDs) - Peripherally inserted central catheter (PICC)
| surgeries | ADVATE - Prophylactic Regimen |
|---|---|
| Surgery: Cimino Shunt | 1 |
| Surgery: PICC Line Insertion in right arm | 1 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Possibly or probably related adverse events
| adverse events | ADVATE - Prophylactic Regimen |
|---|---|
| SAEs | 9 |
| non-SAEs | 1 |
'True' positive inhibitor (PI) defined as any FVIII inhibitor assay result ≥0.6 Bethesda Units (BU)/mL confirmed by central lab on 2 consecutive samples, ie ≥2 PI results (including first PI test, in accordance with study protocol) assessed as either: i. High FVIII inhibitor titer (\> 5 BU/mL) ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL). In addition, to be classified as 'true' positive low FVIII inhibitors titer (≥0.6 - ≤5.0 BU/mL), one of following criteria must be met: - a) Lower or absent therapeutic response at infusion of standard replacement doses ("clinically relevant") as deemed by the clinician in charge. - b) Any lab result of binding FVIII antibodies (IgM, IgA, IgG, IgG1, IgG2, IgG3, or IgG4) must be positive. Classification based on first positive FVIII inhibitor assessment. Inhibitor test result is: - \> 5 BU/mL, then categorized as a high-titer inhibitor - ≥0.6 BU/mL but ≤5 BU/mL, then categorized as a low-titer.
| participants | ADVATE - Prophylactic Regimen |
|---|---|
| Inhibitor Type: Low-Titer | 3 (3.4 to 39.6) |
| Inhibitor Type: High-Titer | 3 (3.4 to 39.6) |
| Inhibitor Type: All Inhibitors | 6 (12.6 to 56.6) |
PUPs = no previous FVIII exposure; MTPs ≤4 previous FVIII exposures 'True' positive inhibitor (PI) = any FVIII inhibitor assay result ≥0.6 Bethesda Units (BU)/mL confirmed by central lab on 2 consecutive samples, ie ≥2 PI results (including first PI test, per study protocol) assessed as either: i. High FVIII inhibitor titer (\>5 BU/mL) ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL). In addition, to be classified as 'true' positive low FVIII inhibitors titer (≥0.6 - ≤5.0 BU/mL), one of following criteria must be met: - a) Lower or absent therapeutic response at infusion of standard replacement doses ("clinically relevant") as deemed by clinician in charge. - b) Any lab result of binding FVIII antibodies (IgM, IgA, IgG, IgG1, IgG2, IgG3, or IgG4) must be positive. Classification based on first positive FVIII inhibitor assessment. Inhibitor test result is: - \> 5 BU/mL, categorized as high-titer inhibitor - ≥0.6 BU/mL but ≤5 BU/mL, categorized as low-titer
| inhibitors | PUPs | MTPs |
|---|---|---|
| Number of Inhibitors in Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) - (Only 'True' Inhibitors) | 3 | 3 |
Collected over 1 year and 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADVATE - Prophylactic Regimen | — | 11/19 (57.9%) | 19/19 (100%) |
| Event | ADVATE - Prophylactic Regimen |
|---|---|
| FACTOR VIII INHIBITIONBlood and lymphatic system disorders | 8/19 |
| HAEMORRHAGEVascular disorders | 2/19 |
| HEAD INJURYInjury, poisoning and procedural complications | 1/19 |
| TRAUMATIC HAEMATOMAInjury, poisoning and procedural complications | 1/19 |
| SOFT TISSUE HAEMORRHAGEMusculoskeletal and connective tissue disorders | 1/19 |
| ARTERIOVENOUS FISTULA OPERATIONSurgical and medical procedures | 1/19 |
| Event | ADVATE - Prophylactic Regimen |
|---|---|
| PYREXIAGeneral disorders | 10/19 |
| RHINITISInfections and infestations | 8/19 |
| NASOPHARYNGITISInfections and infestations | 6/19 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/19 |
| VOMITINGGastrointestinal disorders | 5/19 |
| TEETHINGGastrointestinal disorders | 4/19 |
| DIARRHOEAGastrointestinal disorders | 3/19 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/19 |
| RASHSkin and subcutaneous tissue disorders | 3/19 |
| EAR INFECTIONInfections and infestations | 2/19 |
| Age, Continuous(weeks) | ADVATE - Prophylactic Regimen |
|---|---|
| Mean | 43.3 ± 10.2 |
| Sex: Female, Male(Participants) | ADVATE - Prophylactic Regimen |
|---|---|
| Female | 0 |
| Male | 19 |
| Region of Enrollment(Participants) | ADVATE - Prophylactic Regimen |
|---|---|
| Serbia | 1 |
| United States | 2 |
| Czech Republic | 2 |
| Canada | 1 |
| Spain | 1 |
| Poland | 4 |
| Austria | 1 |
| Russian Federation | 3 |
| Bulgaria | 1 |
| Netherlands | 1 |
| Germany | 2 |
Ran from Aug 2011 to primary completion in Nov 2012, 14 months.
Results were first posted in Oct 2014, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Antihemophilic factor, human recombinant